Matches in SemOpenAlex for { <https://semopenalex.org/work/W2967406639> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2967406639 endingPage "81" @default.
- W2967406639 startingPage "77" @default.
- W2967406639 abstract "Background: The purpose of this study was to assess the antiviral efficacy and safety of the direct-acting antivirals (DAAs) in therapy of chronic hepatitis C virus (HCV) infection. Methods: This real-life multi-centric study was performed at the Clinic for Infectious Diseases, University Clinical Centre of the Republic of Srpska, Banja Luka and it included a total of 89 patients. All patients received the adequate doses of ombitasvir (OBV)/ paritaprevir (PTV)/ritonavir (RTV) + dasabuvir (DSV) plus ribavirin (RBV). RBV was given to all patients except to those with HCV sub-genotype 1b. DSV was not administered to patients infected with HCV genotype 4. For the majority of patients the treatment duration was 12 weeks. For ten patients with liver cirrhosis the duration of treatment was 24 weeks. Viraemia was assessed at three points in time: at baseline, 12 or 24 weeks after the beginning of treatment (end of treatment response - ETR), and 12 weeks after the end of treatment (sustained viral response - SVR). Results: Complete ETR after 12 weeks of treatment was achieved in 79 patients, while in 10 high-risk patients it was achieved after 24 weeks of treatment. Full SVR was recorded in 88 patients 12 weeks after the end of treatment. This therapy was well tolerated and mild adverse effects were recorded in only 10 patients. Conclusion: Treatment of patients with chronic HCV infection with OBV/PTV/ RTV+ DSV + RBV resulted in excellent antiviral activity and mild adverse events." @default.
- W2967406639 created "2019-08-22" @default.
- W2967406639 creator A5036581874 @default.
- W2967406639 creator A5051661565 @default.
- W2967406639 creator A5068470931 @default.
- W2967406639 creator A5089050991 @default.
- W2967406639 date "2019-01-01" @default.
- W2967406639 modified "2023-10-04" @default.
- W2967406639 title "Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in treatment of patients with chronic hepatitis C in the Republic of Srpska: A real-life study" @default.
- W2967406639 cites W1756460431 @default.
- W2967406639 cites W1963484557 @default.
- W2967406639 cites W2133036275 @default.
- W2967406639 cites W2140481064 @default.
- W2967406639 cites W2324515674 @default.
- W2967406639 cites W2411176684 @default.
- W2967406639 cites W2490846324 @default.
- W2967406639 cites W2515727544 @default.
- W2967406639 cites W2522203727 @default.
- W2967406639 cites W2579037114 @default.
- W2967406639 cites W4211051574 @default.
- W2967406639 cites W4240596766 @default.
- W2967406639 doi "https://doi.org/10.5937/scriptamed50-22255" @default.
- W2967406639 hasPublicationYear "2019" @default.
- W2967406639 type Work @default.
- W2967406639 sameAs 2967406639 @default.
- W2967406639 citedByCount "0" @default.
- W2967406639 crossrefType "journal-article" @default.
- W2967406639 hasAuthorship W2967406639A5036581874 @default.
- W2967406639 hasAuthorship W2967406639A5051661565 @default.
- W2967406639 hasAuthorship W2967406639A5068470931 @default.
- W2967406639 hasAuthorship W2967406639A5089050991 @default.
- W2967406639 hasBestOaLocation W29674066391 @default.
- W2967406639 hasConcept C126322002 @default.
- W2967406639 hasConcept C142462285 @default.
- W2967406639 hasConcept C159047783 @default.
- W2967406639 hasConcept C197934379 @default.
- W2967406639 hasConcept C2522874641 @default.
- W2967406639 hasConcept C2776408679 @default.
- W2967406639 hasConcept C2776455275 @default.
- W2967406639 hasConcept C2777100407 @default.
- W2967406639 hasConcept C2778785139 @default.
- W2967406639 hasConcept C2778867932 @default.
- W2967406639 hasConcept C2779298103 @default.
- W2967406639 hasConcept C2780040827 @default.
- W2967406639 hasConcept C2993143319 @default.
- W2967406639 hasConcept C71924100 @default.
- W2967406639 hasConcept C90924648 @default.
- W2967406639 hasConceptScore W2967406639C126322002 @default.
- W2967406639 hasConceptScore W2967406639C142462285 @default.
- W2967406639 hasConceptScore W2967406639C159047783 @default.
- W2967406639 hasConceptScore W2967406639C197934379 @default.
- W2967406639 hasConceptScore W2967406639C2522874641 @default.
- W2967406639 hasConceptScore W2967406639C2776408679 @default.
- W2967406639 hasConceptScore W2967406639C2776455275 @default.
- W2967406639 hasConceptScore W2967406639C2777100407 @default.
- W2967406639 hasConceptScore W2967406639C2778785139 @default.
- W2967406639 hasConceptScore W2967406639C2778867932 @default.
- W2967406639 hasConceptScore W2967406639C2779298103 @default.
- W2967406639 hasConceptScore W2967406639C2780040827 @default.
- W2967406639 hasConceptScore W2967406639C2993143319 @default.
- W2967406639 hasConceptScore W2967406639C71924100 @default.
- W2967406639 hasConceptScore W2967406639C90924648 @default.
- W2967406639 hasIssue "2" @default.
- W2967406639 hasLocation W29674066391 @default.
- W2967406639 hasOpenAccess W2967406639 @default.
- W2967406639 hasPrimaryLocation W29674066391 @default.
- W2967406639 hasRelatedWork W1985671731 @default.
- W2967406639 hasRelatedWork W2193729855 @default.
- W2967406639 hasRelatedWork W2324515674 @default.
- W2967406639 hasRelatedWork W2413331531 @default.
- W2967406639 hasRelatedWork W2582288071 @default.
- W2967406639 hasRelatedWork W2618173141 @default.
- W2967406639 hasRelatedWork W3012688111 @default.
- W2967406639 hasRelatedWork W3031034610 @default.
- W2967406639 hasRelatedWork W4238722043 @default.
- W2967406639 hasRelatedWork W4281556219 @default.
- W2967406639 hasVolume "50" @default.
- W2967406639 isParatext "false" @default.
- W2967406639 isRetracted "false" @default.
- W2967406639 magId "2967406639" @default.
- W2967406639 workType "article" @default.